MX2021004465A - Método para proporcionar la administración subcutánea de anticuerpos anti-cd38. - Google Patents

Método para proporcionar la administración subcutánea de anticuerpos anti-cd38.

Info

Publication number
MX2021004465A
MX2021004465A MX2021004465A MX2021004465A MX2021004465A MX 2021004465 A MX2021004465 A MX 2021004465A MX 2021004465 A MX2021004465 A MX 2021004465A MX 2021004465 A MX2021004465 A MX 2021004465A MX 2021004465 A MX2021004465 A MX 2021004465A
Authority
MX
Mexico
Prior art keywords
subcutaneous administration
monoclonal antibodies
methods
daratumumab
corticosteroid
Prior art date
Application number
MX2021004465A
Other languages
English (en)
Inventor
Donald Raible
Kim Anne Campbell
Ivo Nnane
Cathye Shu
Zhenhua Xu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021004465A publication Critical patent/MX2021004465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos de administración subcutánea de anticuerpos monoclonales anti-CD38, tales como daratumumab; se proporcionan también métodos para el tratamiento de enfermedades autoinmunes con anticuerpos monoclonales anti-CD38 administrados por vía subcutánea. Un corticosteroide se administra opcionalmente antes de la administración subcutánea del anticuerpo anti-CD38 para prevenir y/o reducir los efectos secundarios relacionados con la inyección sistémica.
MX2021004465A 2018-10-17 2019-10-17 Método para proporcionar la administración subcutánea de anticuerpos anti-cd38. MX2021004465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862747107P 2018-10-17 2018-10-17
PCT/US2019/056838 WO2020081881A2 (en) 2018-10-17 2019-10-17 Method of providing subcutaneous administration of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
MX2021004465A true MX2021004465A (es) 2021-08-24

Family

ID=68531583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004465A MX2021004465A (es) 2018-10-17 2019-10-17 Método para proporcionar la administración subcutánea de anticuerpos anti-cd38.

Country Status (11)

Country Link
US (1) US20200121588A1 (es)
EP (1) EP3867275A2 (es)
JP (1) JP2022512722A (es)
KR (1) KR20210077725A (es)
CN (1) CN113195540A (es)
AU (1) AU2019362868A1 (es)
BR (1) BR112021007227A2 (es)
CA (1) CA3116878A1 (es)
MA (1) MA53920A (es)
MX (1) MX2021004465A (es)
WO (1) WO2020081881A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
RS63210B1 (sr) 2015-11-03 2022-06-30 Janssen Biotech Inc Potkožne formulacije anti-cd38 antitela i njihova upotreba
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
TW202235435A (zh) * 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
US20230134748A1 (en) * 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
ATE448323T1 (de) 2003-03-05 2009-11-15 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
SG142330A1 (en) 2004-02-06 2008-05-28 Morphosys Ag De Anti-cd38 human antibodies and uses therefor
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
NZ561883A (en) 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
KR101512853B1 (ko) 2005-10-12 2015-04-28 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
KR20140091038A (ko) * 2011-11-03 2014-07-18 톨러러 세러퓨틱스 인코포레이티드 T-세포 반응의 선택적 억제를 위한 항체 및 방법
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
EP3383903A1 (en) * 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
EP3774915A1 (en) * 2018-03-28 2021-02-17 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies

Also Published As

Publication number Publication date
MA53920A (fr) 2021-09-15
BR112021007227A2 (pt) 2021-08-10
US20200121588A1 (en) 2020-04-23
WO2020081881A2 (en) 2020-04-23
CA3116878A1 (en) 2020-04-23
WO2020081881A3 (en) 2020-05-22
AU2019362868A1 (en) 2021-05-13
CN113195540A (zh) 2021-07-30
EP3867275A2 (en) 2021-08-25
JP2022512722A (ja) 2022-02-07
KR20210077725A (ko) 2021-06-25

Similar Documents

Publication Publication Date Title
MX2021004465A (es) Método para proporcionar la administración subcutánea de anticuerpos anti-cd38.
WO2020081630A3 (en) Robotic animal puzzle
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
WO2013009755A3 (en) Method of use of activated functional proteins to improve animal health
JPS5283911A (en) Fat emulsion for intravenous injection
Ratskiy et al. The T-and B-cell specific immunity of calves under the influence of complex liposomal drug
USD169863S (en) Toy airplane ob similar article
Lim et al. Effect of hCG, LHRHa, ovaprim and pimozide on ovulation induction in long snout bullhead Leiocassis longirotris
Johns Bess
USD150571S (en) Henrichsen automobile
USD168015S (en) Toy animal figure or the like
Al-Slyvany et al. Effect of Vitamins A and E on Some Reproduction Parameters in the Sheep
Al-Shuwaili The effect of adding (Rose marinusofficinalis) and (thymus vulgaris) to broilersdiet on immuneresponse and some physiological parameters of broilers
Mishustina et al. RESPIRATORY SIMULATOR OF «SAMOZDRAV», AS A METHOD OF CARRYING OUT OF HYPOCHICALLY HYPERCAPNIC TRAININGS
USD162766S (en) Holder fob lipsticks ob the like
USD141952S (en) Design fob a target game device
زيد فدعم عسل et al. USE OF SOME OVULATION STIMULANTS IN ARTIFICIAL PROPAGATION OF COMMON CARP (CYPRINUS CARPIO L.)
Cao et al. Effect of green forage on development of the reproductive organ and diversity of the gut microbiota in Meishan prepubertal gilts
USD145732S (en) Design foe a combined doll and parachute
Shelton The Apology for War
Zhang et al. Reducing piglet mortality by early treatment.
Gronbech Two Together
Van Nieuwamerongen et al. Behavioural development of piglets in farrowing crates and in a multi-suckling system
Motko et al. Use of sorbents in growing rabbits
USD168071S (en) Game board for use with marbles